InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
The following is a summary of “Predictive Factors in Asymptomatic Bacteriuria Treatment: Results From a Single-Center Rural Veterans Hospital ,” published in the November 2024 issue of Infectious ...
SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...
The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...
Sulopenem was superior to amoxicillin/clavulanate and ciprofloxacin in treating antimicrobial resistant uncomplicated urinary tract infections. The antibiotic was ...
The newly identified ST164 strain of antibiotic-resistant CRAB bacteria is spreading in Asia, posing a global health risk due to high resistance and limited treatment options. Rigorous infection ...